Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Ahmed, Abubakr ^a   Huai Wang, Jiang ^a   Redmond, H Paul ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 4; MESSENGER RNA; TLR4 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENE SILENCING; IMMUNE SYSTEM; LENTIVIRINAE; LUNG METASTASIS; MOUSE; NONHUMAN; TUMOR VOLUME; WILD TYPE; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL ADHESION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; KNOCKOUT MOUSE; LUNG TUMOR; METABOLISM; NATURAL KILLER CELL; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE SILENCING; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 4; TUMOR CELLS, CULTURED;

EID: 84892784488     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2595-9     Document Type: Article

References (26)

1. Baselga J, Norton L. Focus on breast cancer. Cancer Cell. 2002; 1:319-22.
2. Chambers A, Groom A, MacDonald I. Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563-72.
3. Steeg P. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895-904.
4. Buchholz T, Hill BS, Tucker SL, et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001;7:413-20.
5. Medzhitov R, Preston-Hurlburt P, Janeway C. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394-7.
6. Elson G, Dunn-Siegrist I, Daubeuf B, Pugin J. Contribution of Toll-like receptors to the innate immune response to gram-negative and gram-positive bacteria. Blood. 2007;109:1574-83.
7. Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J. Expression of Toll like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol. 2005;141:298-306.
8. de Bouteiller O, Merck E, Hasan UA, et al. Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem. 2005;280:38133-45.
9. Yu L, Chen S. Toll-like receptors expressed in tumour cells: targets for therapy. Cancer Immunol Immunother. 2008;57: 1271-8.
10. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Tolllike receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. 2009;61:177-97.
11. Hua D, Liu MY, Cheng ZD, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumourigenicity. Mol Immunol. 2009; 46:2876-84.
12. Szczepanski M, Czystowska M, Szajnik M, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumour development and protects the tumour from immune attack. Cancer Res. 2009;69:3105-13.
13. Hiratsuka S, Watanabe A, Sakurai Y, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10:1349-55.
14. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumour cells facilitate evasion of immune surveillance. Cancer Res. 2005; 65:5009-14.
15. Masumoto A, Hemler M. Mutation of putative divalent cation sites in the alpha 4 subunit of the integrin VLA-4: distinct effects on adhesion to CS1/fibronectin, VCAM-1, and invasin. J Cell Biol. 1993;123:245-53.
16. Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP. Endotoxin/lipopolysaccharide activates NF-jB and enhances tumour cell adhesion and invasion through a b1 integrin-dependent mechanism. J Immunol. 2003;170:795-804.
17. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumour cells. Cancer Res. 1987;47:3239-45.
18. Wapnir I, Barnard N, Wartenberg D, Greco R. The inverse relationship between microvessel counts and tumour volume in breast cancer. Breast J. 2001;7:184-8.
19. Feldman J, Goldwasser R, Mark S, Schwartz J, Orion I. A mathematical model for tumour volume evaluation using two dimensions. JAQM. 2009;4:455-61.
20. Otto F, Schmid P, Mackensen A, et al. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer. 1996;32:1712-8.
21. Chicoine MR, Zahner M, Won EK, et al. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery. 2007; 60:372-8.
22. Harmey JH, Bucana CD, Lu W, et al. Lipopolysaccharide induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumour cell invasion. Int J Cancer. 2002;101:415-22.
23. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumour cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68:4026-30.
24. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859-68.
25. Vabulas R, Wagner H, Schild H. Heat shock proteins as ligands of Toll-like receptors. Curr Topics Microbiol Immunol. 2002; 270:169-84.
26. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002;298:1025-9.